Introduction
Parkinson's disease is a major chronic neurodegenerative condition of the elderly.' The basic aetiology of Parkinson's disease remains unknown,2 although recent evidence implicating environmental toxins and free radical damage has accumulated. [3] [4] [5] [6] It has been postulated that antioxidants may have a role in the prevention and/or management of Parkinson's disease. 6 The DATATOP trial7 has shown that the antioxidant Deprenyl (selegiline) significantly delays the need for introduction of levodopa therapy in previously untreated patients. Selegiline has its effect by inhibition of the enzyme monoamine oxidase type B. The data for subjects receiving vitamin E in this study is currently being analysed.
Vitamins A, C and E are all naturally occurring antioxidants. As endogenous oxidative mechanisms appear to be a major factor in the continuing death of dopaminergic neurones and the progression of Parkinson's disease, we have measured concentrations of these vitamins in patients with Parkinson's disease and in a similarly disabled patient group which acted as controls.
Methods
Subjects were recruited over a 6 month period. Two groups were studied; subjects with idiopathic Parkinson's disease and a control group matched for age and sex. The control group was deliberately taken from patients with equivalent disability, albeit from non-neurological disease. The primary diagnoses in this group were: congestive heart failure (7), chronic bronchitis (2) , diabetes mellitus (2) , peripheral vascular disease (3) , rheumatoid arthritis (1) and Paget's diease (1). All these patients had no evidence ofParkinson's disease and a normal blood count and liver function test. The diagnosis of idiopathic Parkinson's disease was established by two of the authors independently. All patients with drug-induced parkinsonism were excluded and all had at least two of the triad: tremor, rigidity and bradykinesia. All patients were on levodopa to which they had had a good response. The duration of the disease was recorded and the degree of disability using the established scale of Hoehn and Yahr.' All subjects gave informed consent before entering the study. Twenty-seven subjects with Parkinson's disease (16 females) with a mean age of 77.1 years (range 58-89 years), and 16 control subjects (nine females) with a mean age of 77.4 years (range 68-87 years) were recruited. All subjects were outpatients.
A sample of venous blood was taken at 9.00 a.m. after an overnight fast. Statistical analysis was performed using SPSS.
Results
The vitamin concentrations and the vitamin E: cholesterol ratio can be seen in the two groups in Figure 1 . In Parkinson's disease the increased dopamine synthesis demanded of surviving nigral neurones increases the production of free radicals,2 and therefore there would be a greater need for scavenging enzymes and antioxidants. It may be postulated therefore that patients with Parkinson's disease would have a reduced level of vitamins A, C and E as these become used up and so afford some protection. Indeed a reduced level of these vitamins due to dietary deficiency or malabsorption may predispose to Parkinson's disease. However, our study shows that patients with Parkinson's disease have normal concentrations of vitamins A and E, and a significantly higher leucocyte vitamin C when compared to certain diseases giving comparable disability. The mean leucocyte vitamin C concentration in the control group was, however, below that of healthy young individuals.
We conclude that elderly patients with Parkinson's disease generally have normal concentrations of the antioxidant vitamins when compared with a similarly disabled elderly group. Vitamin C levels are significantly higher than expected in the Parkinson's disease group. This along with the fact that vitamin A and E are similar in both groups implies it is unlikely that these vitamins have a role to play in the prevention and/or management of elderly Parkinsonian patients. 
